Clinical Trials
13 trialsNCT00049374 2019-10-17
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 2 Completed
NCT00047229 2017-11-08
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
University Health Network, Toronto
Phase 2 Completed
NCT01200342 2016-02-11
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00054639 2014-05-28
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00017589 2014-01-06
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00059813 2013-08-26
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091078 2013-06-05
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00049192 2013-06-04
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079131 2013-06-04
Oblimersen in Treating Patients With Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00042978 2013-01-14
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00080847 2013-01-07
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00301795 2013-01-07
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00085228 2012-09-24
Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed